GoodRx Holdings (GDRX) Common Equity (2019 - 2026)

GoodRx Holdings has disclosed Common Equity across 8 years of filings, most recently posting $647.6 million for Q2 2026.

• In Q2 2026, Common Equity rose 0.71% year-over-year to $647.6 million; the TTM figure through Jun 2026 stood at $647.6 million (up 0.71% YoY), while the FY2025 annual figure was $616.3 million, down 14.96% from the prior year.
• Common Equity came in at $647.6 million for Q2 2026 at GoodRx Holdings, up from $622.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $895.4 million in Q2 2023 to a low of $600.7 million in Q3 2025.
• Average Common Equity over 5 years is $726.6 million, with a median of $710.5 million recorded in 2024.
• Year-over-year, Common Equity advanced 11.78% in 2023 and slipped 25.24% in 2024.
• Over 5 years, Common Equity stood at $814.8 million in 2022, then slipped by 6.49% to $762.0 million in 2023, then decreased by 4.9% to $724.7 million in 2024, then retreated by 14.96% to $616.3 million in 2025, then advanced by 5.09% to $647.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $647.6 million in Q2 2026, $622.0 million in Q1 2026, and $616.3 million in Q4 2025.